<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DIMENHYDRINATE</span><br/>(dye-men-hye'dri-nate)<br/><span class="topboxtradename">Apo-Dimenhydrinate <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Calm-X, </span><span class="topboxtradename">Dimenhydrinate Injection, </span><span class="topboxtradename">Dimentabs, </span><span class="topboxtradename">Dinate, </span><span class="topboxtradename">Dommanate, </span><span class="topboxtradename">Dramanate, </span><span class="topboxtradename">Dramamine, </span><span class="topboxtradename">Dramilin, </span><span class="topboxtradename">Dramocen, </span><span class="topboxtradename">Dramoject, </span><span class="topboxtradename">Dymenate, </span><span class="topboxtradename">Gravol <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Hydrate, </span><span class="topboxtradename">Marmine, </span><span class="topboxtradename">Motion-Aid, </span><span class="topboxtradename">Nauseatol <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Novodimenate <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">PMS Dimenhydrinate <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Travamine <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Travel Aid, </span><span class="topboxtradename">Travel Eze, </span><span class="topboxtradename">Wehamine<br/></span><b>Classifications:</b> <span class="classification">antihistamine (h<sub>1</sub>-receptor antagonist)</span>; <span class="classification">antiemetic</span>; <span class="classification">antivertigo agent</span><br/><b>Prototype: </b>Diphenhydramine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg tablets; 50 mg/mL injection; 15.62 mg/5 mL, 12.5 mg/4 mL, 12.5 mg/5 mL liquid</p>
<h1><a name="action">Actions</a></h1>
<p>H<sub>1</sub>-receptor antagonist and salt of diphenhydramine, with which it shares similar properties.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Precise mode of antinauseant action not known, but thought to involve ability to inhibit cholinergic stimulation in vestibular
         and associated neural pathways.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Chiefly in prevention and treatment of motion sickness. Also has been used in management of vertigo, nausea, and vomiting
         associated with radiation sickness, labyrinthitis, Ménière's syndrome, stapedectomy, anesthesia, and various medications.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Narrow-angle glaucoma, prostatic hypertrophy. Safe use during pregnancy (category B), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Convulsive disorders.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Motion Sickness</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50100 mg q46h (max: 400 mg/24 h) <span class="rdroute">IV/IM</span> 50 mg as needed<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>26 y</i>, up to 25 mg q68h (max: 75 mg/24 h); <i>612 y</i>, 2550 mg q68h (max:150 mg/24 h) <span class="rdroute">IV/IM</span>
<i>26 y</i>, 1.25 mg/kg q.i.d. up to 300 mg/d; <i>612 y</i>, 1.25 mg/kg q.i.d. up to 300 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: Give 3060 min before treatment, then repeat 90 min after treatment, and again in 3 h to prevent radiation sickness.
            			
         </li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give undiluted and inject deep IM into a large muscle.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute each 50 mg in 10 mL of NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give each 50 mg or fraction thereof over 2 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<b>Aminophylline,</b>
<b>amobarbital,</b>
<b>butorphanol,</b>
<b>chlorpromazine,</b>
<b>glycopyrrolate,</b>
<b>hydroxyzine,</b>
<b>midazolam,</b>
<b>pentobarbital,</b>
<b>prochlorperazine,</b>
<b>promazine,</b>
<b>promethazine,</b>
<b>thiopental.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store preferably at 15°30° C (59°86° F), unless otherwise directed by manufacturer. </li>
<li>Examine parenteral preparation for particulate matter and discoloration. Do not use unless absolutely clear.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness,</span> headache, incoordination, dizziness, blurred vision, nervousness, restlessness, <span class="speceff-common">insomnia (especially children).</span>
<span class="typehead">CV:</span> Hypotension, palpitation. <span class="typehead">GI:</span> Dry mouth, nose, throat; anorexia, constipation or diarrhea. <span class="typehead"> Urogenital:</span>  Urinary frequency, dysuria. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>
<span class="alt">Skin testing</span> procedures should not be performed within 72 h after use of an antihistamine.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> and other <span class="classification">cns depressants</span> enhance CNS depression, drowsiness; <span class="classification">tricyclic antidepressants</span> compound anticholinergic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 1530 min PO; immediate IV; 2030 min IM. <span class="typehead">Duration:</span> 36 h. <span class="typehead">Distribution:</span> Distributed into breast milk. <span class="typehead">Elimination:</span> Excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Use side rails and supervise ambulation; drug produces high incidence of drowsiness.</li>
<li>
            							Note: Tolerance to CNS depressant effects usually occurs after a few days of drug therapy; some decrease in antiemetic action may
            result with prolonged use.
            						
         </li>
<li>Monitor for dizziness, nausea, and vomiting; these may indicate drug toxicity.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Take 30 min before departure to prevent motion sickness; repeat before meals and upon retiring.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>